vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
AVAX ONE TECHNOLOGY LTD. is the larger business by last-quarter revenue ($1.0M vs $829.5K, roughly 1.2× China SXT Pharmaceuticals, Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -1633.6%, a 1536.8% gap on every dollar of revenue.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
AVX vs SXTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $829.5K |
| Net Profit | $-16.6M | $-802.6K |
| Gross Margin | — | 16.2% |
| Operating Margin | -1522.1% | -76.9% |
| Net Margin | -1633.6% | -96.8% |
| Revenue YoY | — | 0.0% |
| Net Profit YoY | -480.2% | 0.0% |
| EPS (diluted) | $32.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | — | ||
| Q3 25 | $525.9K | $829.5K | ||
| Q2 25 | $452.0K | — | ||
| Q1 25 | $344.4K | — | ||
| Q3 24 | $0 | $829.5K | ||
| Q2 24 | $41.3K | — | ||
| Q3 23 | — | $939.6K | ||
| Q3 22 | — | $1.2M |
| Q4 25 | $-16.6M | — | ||
| Q3 25 | $-8.4M | $-802.6K | ||
| Q2 25 | $-8.1M | — | ||
| Q1 25 | $-145.5K | — | ||
| Q3 24 | $-5.8M | $-802.6K | ||
| Q2 24 | $-4.2M | — | ||
| Q3 23 | — | $-9.7M | ||
| Q3 22 | — | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 16.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | — | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | 18.4% | — | ||
| Q3 23 | — | 30.7% | ||
| Q3 22 | — | 7.4% |
| Q4 25 | -1522.1% | — | ||
| Q3 25 | -496.6% | -76.9% | ||
| Q2 25 | -328.4% | — | ||
| Q1 25 | -600.0% | — | ||
| Q3 24 | — | -76.9% | ||
| Q2 24 | -2827.7% | — | ||
| Q3 23 | — | -995.0% | ||
| Q3 22 | — | -95.2% |
| Q4 25 | -1633.6% | — | ||
| Q3 25 | -1588.0% | -96.8% | ||
| Q2 25 | -1783.4% | — | ||
| Q1 25 | -42.2% | — | ||
| Q3 24 | — | -96.8% | ||
| Q2 24 | -10243.5% | — | ||
| Q3 23 | — | -1032.0% | ||
| Q3 22 | — | -123.7% |
| Q4 25 | $32.17 | — | ||
| Q3 25 | $-5.55 | — | ||
| Q2 25 | $-27.60 | — | ||
| Q1 25 | $-1.17 | — | ||
| Q3 24 | $-57.19 | $-0.25 | ||
| Q2 24 | $-83.03 | — | ||
| Q3 23 | — | $-19.34 | ||
| Q3 22 | — | $-14.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $187.0M | $15.4M |
| Total Assets | $195.0M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | — | ||
| Q3 25 | $894.7K | $18.1M | ||
| Q2 25 | $185.3K | — | ||
| Q1 25 | $1.4M | — | ||
| Q3 24 | — | $18.5M | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $11.5M | ||
| Q3 22 | — | $3.0M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | $105.0K | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q3 24 | $2.2M | $952.3K | ||
| Q2 24 | $3.1M | — | ||
| Q3 23 | — | $106.6K | ||
| Q3 22 | — | — |
| Q4 25 | $187.0M | — | ||
| Q3 25 | $12.2M | $15.4M | ||
| Q2 25 | $4.1M | — | ||
| Q1 25 | $6.4M | — | ||
| Q3 24 | $6.7M | $15.0M | ||
| Q2 24 | $11.3M | — | ||
| Q3 23 | — | $5.1M | ||
| Q3 22 | — | $14.5M |
| Q4 25 | $195.0M | — | ||
| Q3 25 | $16.5M | $21.7M | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $16.8M | — | ||
| Q3 24 | $10.8M | $31.0M | ||
| Q2 24 | $15.7M | — | ||
| Q3 23 | — | $14.6M | ||
| Q3 22 | — | $22.2M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | 0.01× | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q3 24 | 0.33× | 0.06× | ||
| Q2 24 | 0.28× | — | ||
| Q3 23 | — | 0.02× | ||
| Q3 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-1.4M |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -216.2% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | — | ||
| Q3 25 | $-2.4M | $-1.4M | ||
| Q2 25 | $-884.1K | — | ||
| Q1 25 | $-2.2M | — | ||
| Q3 24 | $-1.2M | $-1.4M | ||
| Q2 24 | $-919.2K | — | ||
| Q3 23 | — | $-579.6K | ||
| Q3 22 | — | $-549.1K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -216.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
